| Entries |
| Document | Title | Date |
|---|
| 20080199527 | Enteric Coated Azithromycin Multiparticulates - A pharmaceutical composition is disclosed which comprises multiparticulates wherein said multiparticulates further comprise an azithromycin core and an enteric coating disposed upon said azithromycin core. | 08-21-2008 |
| 20080226738 | Sustained-Released Pellet Formulation of Alpha1-Receptor Antagonist and Process For the Preparation Thereof - A sustained-release pellet formulation comprising: a pellet core comprising an α1-receptor antagonist, a pellet-forming substance and a pharmaceutically acceptable excipient and a coating layer comprising an enteric coating substance and a water-insoluble polymer, which is coated on said pellet core maintains a therapeutically effective drug level in the blood for a sufficient time without an initial burst and sustains the release of the drug even in the small intestine due to the water-insoluble polymer in the coating layer | 09-18-2008 |
| 20080248124 | Process for producing pharmaceutical composition - The present invention relates to a process for producing a pharmaceutical composition which can stably contain an active ingredient unstable against water and can sustained-release such the active ingredient for a long period of time by remaining at an administrated portion as well as a pharmaceutical composition produced by the same. Specifically, the present invention relates to a process for producing a pharmaceutical composition, comprising steps of: mixing and heating a first phase, prepared by mixing a polyhydric alcohol and a salt, and a second phase containing a water-soluble polymer under a reduced pressure, before evaporating substantially all water in the first phase by mixing and heating a mixture of first and second phases under a reduced pressure or after evaporating substantially all water in the first phase by mixing and heating the first phase under a reduced pressure; and adding a third phase containing an active ingredient unstable against water and mixing them to obtain the pharmaceutical composition, as well as a pharmaceutical composition produced the same. | 10-09-2008 |
| 20080260844 | Solid, Oral, Microparticulate Dosage Form Which Has Been Designed To Prevent Misuse - The invention relates to the field of solid, oral, microparticulate dosage forms having a composition that prevents the misuse of the active pharmaceutical ingredient contained therein. The aim of the invention is to prevent the improper use of solid oral medicaments for any use other than the therapeutic use(s) officially approved by the appropriate public health authorities. More specifically, the invention relates to a solid, oral drug form which is characterised in that at least one part of the active pharmaceutical ingredient is contained in the microparticles thereof and in that the inventive form comprises anti-crushing means which are intended to impede or completely prevent the crushing of the microparticles of the active pharmaceutical ingredient, such as to preclude the misuse thereof. | 10-23-2008 |
| 20080286373 | Ziprasidone formulations - A ziprasidone formulation containing at least (a) one ziprasidone compound and at least an excipient component (b) that includes at least one of
| 11-20-2008 |
| 20090011033 | PROCESS FOR THE MANUFACTURE OF CELLULOSE SULFATE WITH IMPROVED CHARACTERISTICS - The invention refers to a method for the production of cellulose sulfate which is completely water-soluble and has an adjustable solution viscosity in aqueous solution, which qualifies the produced sodium cellulose sulfate (SCS) as auxiliary material with ideal biological compatibility for biological and medical applications, in particular it is suitable for the encapsulation and immobilization of biological objects, e.g. tissue, cells, microorganisms, enzymes or viruses in microcapsule. | 01-08-2009 |
| 20090017125 | Drug carrier pellet production process - The invention provides a process for the production of drug carrier pellets comprising spray-dried pellets comprising spray-drying a solution of a physiologically tolerable cellulosic binder containing a physiologically tolerable inert particulate carrier having a particle size D (v.0.5) of less than 50 μm. | 01-15-2009 |
| 20090022809 | STABLE TASTE MASKED FORMULATIONS OF CEPHALOSPORINS - A stable taste masked, pharmaceutical composition comprising a plurality of coated, non-disintegrating discrete dosage units, said units comprising of a core comprising one or more cephalosporins such as cefuroxime axetil and cefpodoxime proxetil and one or more coating layers. Cefuroxime axetil is in α-crystalline and amorphous forms, where at least 30% of the Cefuroxime axetil is in the α-crystalline form, wherein the particle size distribution of the α-crystalline form being such that 100% of the particles have a particle size below 250μ. The ratio of the crystalline fraction to the amorphous fraction ranges from 0.3:0.7 to 0.99:0.01. The particle size of cefpodoxime proxetil is such that 90% of the particles are below 15μ. The process of preparation of coated, non-disintegrating pellets comprising the steps of reducing the particle size of the one or more cephalosporins, blending with the other excipients, wet granulation, extrusion, spheronization, drying and screening to obtain pellets, said pellets being further coated with one or more layers of film coating to achieve taste masking. | 01-22-2009 |
| 20090123554 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations - The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval. | 05-14-2009 |
| 20090162449 | STABLE ORAL BENZIMIDAZOLE COMPOSITIONS AND PROCESS OF PREPARATION THEREOF - The present invention relates to stable oral compositions of one or more benzimidazole compounds and processes for their preparation. Also provided are methods for treating various gastrointestinal disorders. | 06-25-2009 |
| 20090196934 | SPHERICAL ELEMENTARY GRANULE AND METHOD FOR PRODUCTION THEREOF - The characteristic in being coated with film of spherical elementary granules is improved by adjusting a short/long diameter-ratio distribution coefficient to a specific value. | 08-06-2009 |
| 20090196935 | Pharmaceutical Capsules Comprising Extended Release Dipyridamole Pellets - The present invention is directed to pharmaceutical capsules comprising extended release formulations of dipyridamole, processes for preparing such dipyridamole extended release formulations and their use in the treatment of stroke. | 08-06-2009 |
| 20090280186 | PROCESS FOR PRODUCING SPHERICAL BASE GRANULE COMPRISING EASILY WATER-SOLUBLE DRUG - Provided is a process for producing spherical base granules comprising a easily water-soluble drug and suited for film coating by spraying a layering liquid over pharmaceutically inert spherical core particles, thereby coating the particles with a layer comprising the easily water-soluble drug, wherein (1) the spherical core particles have a microcrystalline cellulose content of 30 mass % or greater and a water absorbing capacity of 0.5 cm | 11-12-2009 |
| 20100068291 | Oral Medicament Based on a Proton Pump Inhibitor - The invention relates to oral medicaments having a modified release of proton pump inhibitors (PPI's) that are, in particular, useful in preventing and treating gastrointestinal disorders. The aim of the invention is to provide a novel oral medicament based on PPI's ideally having all or some of the following characteristics: a) quickly providing relief to the patient by increasing the gastric pH after oral administration of the medicament; b) accelerating the recovery of patients while maintaining this increase in the gastric pH for as long as possible after oral administration of the medicament and, in particular, during the night; c) improving the observance of the treatment and the comfort of the patient by taking the medicament once daily. To this end, the microcapsules of the invention, preferably non-enteric, are constituted of PPI microparticles coated with ethyl cellulose, an ammonio methacrylate copolymer (Eudragit® RL 100), polyvinylpyrrolidone, castor oil and polyoxyethylenated hydrogenated castor oil ( | 03-18-2010 |
| 20100159018 | Venlafaxine Formulations and Methods of Preparing the Same - A method of forming a multi-particulate dosage form using rotary granulation is described in which polyethylene oxide is employed as s binder in a rotary granulation process. A multi-particulate oral dosage form comprises a plurality of pellets, the pellets comprising a core having disposed thereon a core composition layer. The core composition layer comprises venlafaxine and a binder, wherein the binder comprises a polyethylene oxide. In other embodiments, the binder comprises a 1:2:1 bis (butyl methacrylate-co-(2-dimethylaminoethyl)methacrylate-co-methyl methacrylate. | 06-24-2010 |
| 20100178353 | QUICK DISSOLVE COMPOSITIONS AND TABLETS BASED THEREON - The invention provides a composition useful for making oral dosage forms capable of dissolving in the mouth in less than 40 seconds without the need for a conventional super disintegrant and having a friability of less than 1%; wherein the composition includes liquiflash particles and an excipient mass. A preferred excipient mass according to the invention contains a directly compressible inorganic salt; a cellulose derivative or a combination of a directly compressible inorganic salt and a cellulose derivative. Preferably, the liquiflash particles and the excipient mass are combined in proportions such that the active ingredient remains substantially within the microspheres when the composition is compressed to obtain a dosage form having a hardness of 20 to 50 N. The compositions of the invention allow for the fabrication of oral dosages having improved hardness and friability. | 07-15-2010 |
| 20100215759 | PHARMACEUTICAL COMPOUNDS - Condensed tricyclic pyrazole compounds having affinity for the CB1 and/or CB2 cannabinoidergic receptors, with activity both on the peripheral and central nervous system, of formula (I): | 08-26-2010 |
| 20100233278 | RAPIDLY DISINTEGRATING SOLID PREPARATION - Provided is a solid preparation which rapidly disintegrates in the presence of saliva or a small amount of water in the oral cavity, particularly, a rapidly disintegrating solid preparation useful as an orally-disintegrating solid preparation. | 09-16-2010 |
| 20100255109 | STABILIZED ANTIOXIDANT PARTICLES, COMPOSITION COMPRISING THE SAME AND METHOD FOR PREPARING THE SAME - The present invention provides stabilized antioxidant particles, each of which includes a core consisting of an antioxidant and a first coating layer formed on the surface of the core, wherein the first coating layer is formed by polymerizing at least one α-lipoic acid or its derivative, a composition including the same, and a method for preparing the same. | 10-07-2010 |
| 20100260859 | CONTROLLED-RELEASE CLOZAPINE COMPOSITIONS - A composition for delivery of a drug is disclosed. The composition has a semipermeable coating, particles of clozapine having an effective average particle size of less than or about 2 μm and at least one surface stabilizer adsorbed on the surface of the clozapine particles, and a solubilizing agent. | 10-14-2010 |
| 20100272819 | PRODUCTION OF CELLULOSE NANOPARTICLES - The present invention relates to novel nanoparticles based on cellulose and a process for producing them and their use. | 10-28-2010 |
| 20100278925 | FORMULATIONS OF ORGANO-PLATINIC COMPOUNDS IN THE PRESENCE OF ASSOCIATIVE POLYMERS, PRODUCTS THUS OBTAINED AND USES THEREOF - The invention consists of formulations based on compounds of platinum encapsulated by associative and water-soluble polymers. These formulations are in aqueous form or in the form of granulates. The invention further pertains to pharmaceutical preparations which contain these formulations, and their implementation in the fabrication of an orally administered medication, in polychemotherapy treatments. | 11-04-2010 |
| 20100303919 | PHARMACEUTICAL COMPOSITIONS COMPRISING FLUVASTATIN - Pharmaceutical compositions comprising fluvastatin, HPMC and optionally other pharmaceutical excipients which are colour-stable upon prolonged periods of storage. | 12-02-2010 |
| 20100310667 | CONTROLLED-RELEASE FLOATING PHARMACEUTICAL COMPOSITIONS - The invention relates to a pharmaceutical composition comprising a plurality of controlled-release coated microparticles each comprising a floating core, on the surface of which is deposited a layer containing at least one active principle, said layer being covered with a controlled-release coating, characterized by the fact that said floating core is composed of cellulose acetate phthalate and has an apparent density of less than or equal to 0.6 g/mL and said coated microparticles have a density of less than or equal to 0.7 g/mL. | 12-09-2010 |
| 20100310668 | PHARMACEUTICAL COMPOSITIONS COMPRISING N-[2-(DIETHYLAMINO)ETHYL]-5-[(5-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDE- NE)METHYL]-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE - The present invention relates to a pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide or a pharmaceutically acceptable salt thereof as active pharmaceutical ingredient. | 12-09-2010 |
| 20100330189 | SUSTAINED RELEASE BEADS AND SUSPENSIONS INCLUDING THE SAME FOR SUSTAINED DELIVERY OF ACTIVE INGREDIENTS - Sustained-released beads providing active ingredients over an extended period of time to an individual orally ingesting the sustained release beads. The sustained-release beads can be part of a suspension wherein the sustained-release beads are suspended and evenly dispersed in the suspension. Binding agents are used to form the structural framework of the sustained released beads and retain the active ingredients without chemical or electrical bonding. The components of the dispersion medium are GRAS designated, making the suspension suitable for use as a food product. | 12-30-2010 |
| 20110003005 | Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions - Extended release ondansetron compositions of the present invention are useful for treating postoperative nausea and vomiting (PONV) and/or postdischarge nausea and vomiting (PDNV). | 01-06-2011 |
| 20110033546 | Pure sustained dichroa ferbrifuga alkone formulation - Now is provided a new sustained release drug preparation comprising such an inclusion complex of a medical compound with | 02-10-2011 |
| 20110091563 | ORALLY-DISINTERGRATING SOLID PREPARATION - The present invention provides an orally-disintegrating solid preparation such as a tablet produced by tabletting fine granules showing controlled release of a pharmaceutically active ingredient and an additive, and the like, and the orally-disintegrating solid preparation containing fine granules coated with a coating layer containing a polymer affording a casting film having an elongation at break of about 100-about 700%. With the preparation, breakage of fine granules during tabletting can be suppressed in the production of an orally-disintegrating solid preparation containing fine granules showing controlled release of a pharmaceutically active ingredient. | 04-21-2011 |
| 20110097415 | Sustained release of pharmaceutical composition containing a safe botanic drug for the treating and preventing of diabetes - The present invention is providing a new sustained release drug preparation comprising such and inclusion complex of a medical compound with safe botanic drug (SBD), which sustains or retards the dissolution and release of the SBD at a controlled rate from the inclusion complex and hence from the drug preparation containing the SBD, so as to maintain the concentration of the SBD in blood at an effective level for prolonged time. | 04-28-2011 |
| 20110117205 | ORAL PHARMACEUTICAL FORMULATION IN THE FORM OF AQUEOUS SUSPENSION FOR MODIFIED RELEASE OF ACTIVE PRINCIPLE(S) - The invention relates to liquid pharmaceutical formulations for oral administration with the modified release of active principle(s), excluding amoxicillin, said formulations consisting of suspensions of coated particles of active principles (microcapsules). According to the invention, the microcapsules constituting the disperse phase of the suspension are designed to allow the modified release of the active principle(s) according to a profile that does not change during the storage of the liquid suspension. To do this the inventors propose the selection of a specific coating composition for the microcapsules which consists of at least four components that allow these microcapsules to be stored in water without modifying their properties of modified release of the active principle, this liquid phase furthermore being saturated with active principle(s). | 05-19-2011 |
| 20110123633 | STABLE DIGESTIVE ENZYME COMPOSITIONS - Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing. | 05-26-2011 |
| 20110123634 | STABLE DIGESTIVE ENZYME COMPOSITIONS - Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing. | 05-26-2011 |
| 20110129538 | PROCESS FOR PREPARING ORALLY ADMINISTERED DABIGATRAN FORMULATIONS - The invention relates to an improved process for preparing a new medicament formulation of the active substance dabigatran etexilate of formula I | 06-02-2011 |
| 20110129539 | ORAL PHARMACEUTICAL FORMULATION IN THE FORM OF AN AQUEOUS SUSPENSION OF MICROCAPSULES FOR MODIFIED RELEASE OF AMOXICILLIN - The invention concerns liquid pharmaceutical formulations, for oral delivery, with modified release of amoxicillin and consisting of suspensions of coated particles of amoxicillin (microcapsules). The microcapsules constituting the dispersed phase of the suspension are designed, according to the invention, to enable modified release of amoxicillin, in accordance with a profile which remains unaltered during the shelf life of the liquid suspension. Therefor, the invention consists in selecting a coating composition specific to the microcapsules consisting of at least four components enabling preservation of said microcapsules in water without altering their properties of modified release of amoxicillin, said liquid phase being furthermore saturated with amoxicillin. | 06-02-2011 |
| 20110165257 | COATED DRUG SPHEROIDS AND USES THEREOF FOR ELIMINATING OR REDUCING CONDITIONS SUCH AS EMESIS AND DIARRHEA - The present invention provides an oral pharmaceutical formulation comprising coated spheroids of a kinase inhibitor such as neratinib, which formulation is designed to reduce or eliminate side effects associated with existing oral formulations of kinase inhibitors. | 07-07-2011 |
| 20110244049 | COMPOSITIONS COMPRISING 4-(2-(5-BROMO-4-(1-CYCLOPROPYLNAPHTHALEN-4-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)- ACETAMIDO)-3-CHLOROBENZOIC ACID AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND METHODS FOR PREPARING AND USING SAME - The present invention relates to compositions comprising 4-(2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4H-1,2,4-triazol-3-ylthio)acetamido)-3-chlorobenzoic acid or pharmaceutically acceptable salts thereof, and to the preparation and use of such compositions, in particular for the treatment of diseases. | 10-06-2011 |
| 20110244050 | PULSED-RELEASE SILDENAFIL COMPOSITION AND METHOD FOR PREPARING SAID COMPOSITION - The present invention relates to a pulsed-release sildenafil pharmaceutical composition comprising an immediate release fraction containing from 5 to 100 mg of sildenafil and a controlled release fraction containing from 25 to 150 mg of sildenafil, wherein the controlled release fraction is comprised of particles containing (a) a superdisintegrant agent (b) a coating comprising at least one pH-dependent solubility polymer and at least one pH-independent solubility polymer and (c) optionally, other pharmaceutical excipients. The composition of the present invention exhibits a faster dissolution profile in alkaline media than in acid media, which allows for obtaining enhanced pulsed-release formulations. | 10-06-2011 |
| 20110280945 | NOVEL METHOD FOR THE PREPARATION OF GRANULATES OF ACTIVE CONSTITUENTS, AND GRANULATES AS OBTAINED - The present invention relates to a method for preparing a granulate of at least two active principles, including a step of applying said active principles to a solid particulate medium by dusting, said active principles not being plant extracts. | 11-17-2011 |
| 20110293729 | NOVEL COMPOSITION BASED ON GAMMA-HYDROXYBUTYRIC ACID - The present invention relates to a granule of gamma-hydroxybutyric acid or of one of its pharmaceutically acceptable salts, characterized in that it comprises a solid core on which the gamma-hydroxybutyric acid or one of its salts is supported. | 12-01-2011 |
| 20120027864 | COATED DRUG DELIVERY FORMULATIONS - The invention relates generally to methods of making formulations for delivering biological agents to a patient. In one aspect, proliposomal drug-delivery systems for medicaments are provided. In another aspect, coated proliposomal formulations for poorly water soluble drugs, and methods for making the same, are provided. Certain embodiments of the present invention provide enhanced stability and bioavailability for pharmaceutical formulations. | 02-02-2012 |
| 20120058194 | PHARMACEUTICAL FORMULATIONS COMPRISING SUBSTITUTED BENZIMIDAZOLE DERIVATIVES - Stabilized substituted benzimidazole modified release pharmaceutical formulations with at least two drug-containing fractions, wherein the release from a first fraction precedes the release from a second fraction, pharmaceutical excipients, processes for preparing the stable formulations, packaging therefor, and their use in treatment of erosive esophagitis and heartburn associated with non-erosive gastroesophageal reflux disease. | 03-08-2012 |
| 20120082729 | QUICK DISSOLVE COMPOSITIONS AND TABLETS BASED THEREON - The invention provides a composition useful for making oral dosage forms capable of dissolving in the mouth in less than 40 seconds without the need for a conventional super disintegrant and having a friability of less than 1%; wherein the composition includes liquiflash particles and an excipient mass. A preferred excipient mass according to the invention contains a directly compressible inorganic salt; a cellulose derivative or a combination of a directly compressible inorganic salt and a cellulose derivative. Preferably, the liquiflash particles and the excipient mass are combined in proportions such that the active ingredient remains substantially within the microspheres when the composition is compressed to obtain a dosage form having a hardness of 20 to 50 N. The compositions of the invention allow for the fabrication of oral dosages having improved hardness and friability. | 04-05-2012 |
| 20120141592 | CONTROLLED-RELEASE GRANULAR COMPOSITIONS CONTAINING MESALAZINE AND PROCESS FOR THE MANUFACTURE THEREOF - The present invention refers to controlled release granular compositions of mesalazine and their use in the treatment of inflammatory pathologies of the intestinal tract. The aforesaid granular compositions comprise: a) a central core comprising an inert substrate; b) an intermediate layer comprising mesalazine and one or more physiologically acceptable excipients; c) a gastro-resistant coating. The present invention then refers to a process for obtaining the aforesaid granular compositions. | 06-07-2012 |
| 20120164233 | PULSATILE RELEASE PHARMACEUTICAL FORMULATION OF DEXLANSOPRAZOLE - The present invention relates to a pulsatile-release pharmaceutical formulation of dexlansoprazole composed of a single type of enteric coated pellets and the process for the preparation thereof. | 06-28-2012 |
| 20120171296 | RAPIDLY DISINTEGRATING SOLID PREPARATION - Provided is a solid preparation which rapidly disintegrates in the presence of saliva or a small amount of water in the oral cavity, particularly, a rapidly disintegrating solid preparation useful as an orally-disintegrating solid preparation. | 07-05-2012 |
| 20120207843 | FLOATING MICROGRANULES - A floating granule having a solid core, on which an active ingredient is supported, and a compound capable of generating a gas discharge which is constituted by an alkaline agent, characterised in that it does not comprise an acid agent that is capable of generating a gas discharge. | 08-16-2012 |
| 20120231083 | SUSTAINED RELEASE CANNABINOID MEDICAMENTS - The present invention provides a medicament which results in delivery of a therapeutic level of one or more cannabinoids during a clinically relevant therapeutic window. The therapeutic window is a longer window than provided by an immediate release medicament such as Marinol containing an equivalent amount of the cannabinoid. Oral administration of the present compositions provides therapeutic dosing while maintaining safe, side effect sparing, levels of a cannabinoid. The present invention also provides methods of treating cannabinoid-sensitive disorders. | 09-13-2012 |
| 20120231084 | GALENIC FORM SUITABLE FOR ABSORBING, IN A SPECIFIC MANNER, THE UNDESIRABLE MOLECULES IN THE DIGESTIVE TRACT - The present invention relates to a galenic form comprising particles capable of specifically adsorbing the undesirable molecules present in the digestive tract, to the method for preparing same and to the use thereof in particular for producing a medicine intended for preventing or treating undesirable effects linked to an imbalance of the intestinal and/or colonic flora that can result for example from treatment with antibiotics. | 09-13-2012 |
| 20120258177 | MICROCAPSULES COMPRISING BENZOYL PEROXIDE AND TOPICAL COMPOSITIONS COMPRISING THEM - The present invention provides microcapsules comprising benzoyl peroxide and topical compositions comprising them, optionally along with other active ingredients, particularly for the treatment of acne. | 10-11-2012 |
| 20120315337 | MULTIPARTICULATE 5-HTP COMPOSITIONS AND RELATED METHODS - Enteric coated multiparticulate compositions that use 5-HTP as an active ingredient are disclosed. The multiparticulates have a spheroidal core comprising 5-HTP, microcrystalline cellulose, and hydroxypropyl methylcellulose; a sub-coat comprising hydroxypropyl methylcellulose on the spheroidal core; and an enteric coat on the sub-coated spheroidal core. The average diameter of the particulates is about 0.1-3 mm. Other aspects of the invention include methods of making and methods of using the multiparticulate compositions. | 12-13-2012 |
| 20130071481 | COATED PARTICLE AND METHOD FOR PRODUCING COATED PARTICLE - The present invention relates to a coating particle containing a nuclear particle covered with a coating layer, and in the coating particle, the coating layer is a layer containing hydroxyalkyl cellulose and a binder. | 03-21-2013 |
| 20130177652 | PHARMACEUTICAL ORAL DOSAGE FORMS COMPRISING DABIGATRAN ETEXILATE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS - The invention relates to pharmaceutical oral dosage forms of the active substance ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate (dabigatran etexilate) and the pharmacologically acceptable salts thereof, in particular dabigatran etexilate methanesulfonate. | 07-11-2013 |
| 20130195986 | New Particles of Tetracyclines and Protecting Agent - Particles containing a tetracycline or one of its pharmaceutically acceptable salts and an antioxidant, formulations containing the same and their use in the treatment of infectious diseases are described. Methods of encapsulation of a tetracycline or one of its pharmaceutically acceptable salts and an antioxidant are also disclosed. | 08-01-2013 |
| 20130209567 | Modified Release Dosage Forms of Skeletal Muscle Relaxants - A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once—daily oral administration to maintain an adequate plasma concentration—time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period. | 08-15-2013 |
| 20130230596 | Abuse-Resistant Oral Dosage Forms And Method Of Use Thereof - An opioid-antagonist oral dosage form which does not release a therapeutically effective amount of the opioid antagonist when the oral dosage form is orally administered to a human being, but whereby a physical alteration of the oral dosage form results in a release of the therapeutically effective amount of the opioid antagonist. An embodiment of the oral dosage form includes an opioid-antagonist layer coated onto a biologically inert pellet, and a non-releasing membrane coated onto the opioid-antagonist layer. Optionally, the oral dosage form can also include an opioid agonist, such that a method of preventing the abuse of an oral dosage form of an opioid agonist is provided by forming the oral dosage form including an opioid agonist and an opioid antagonist. | 09-05-2013 |
| 20130236554 | DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME - The invention relates to dosage forms that provide prolonged therapy. In particular, the invention relates to dosage forms including various pluralities of drug-containing resin particles. The invention also relates to methods of making these dosage forms and methods of treating using these dosage forms. | 09-12-2013 |
| 20130243869 | DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME - The invention relates to dosage forms that provide prolonged therapy. In particular, the invention relates to dosage forms including various pluralities of drug-containing resin particles. The invention also relates to methods of making these dosage forms and methods of treating using these dosage forms. | 09-19-2013 |
| 20130243870 | HYDROXYALKYL CELLULOSE - The present invention provides a hydroxyalkyl cellulose having a viscosity of 1.10 mPa·s to 1.95 mPa·s in a 2%-concentration aqueous solution at 20° C., and a solid formulation containing the hydroxyalkyl cellulose. | 09-19-2013 |
| 20130259947 | ORAL METRONIDAZOLE PHARMACEUTICAL COMPOSITIONS - The present invention relates to an oral pharmaceutical composition comprising metronidazole, wherein metronidazole is released from the composition generally at the pH 5.0 and above. | 10-03-2013 |
| 20130295188 | BULK ENTERIC CAPSULE SHELLS - The present disclosure relates to aqueous composition comprising hydroxypropyl methyl cellulose acetate succinate (HPMCAS) polymer dispersed in water, wherein the dispersed polymer is partially neutralized with at least one alkaline material. The instant disclosure also relates to compositions for use in methods of making capsule shells endowed with bulk enteric properties. The present disclosure also relates to capsules made according with the compositions and methods of the present disclosure. | 11-07-2013 |
| 20130295189 | METHOD FOR MANUFACTURING ACID PELLETS - The invention relates to an improved method of manufacturing substantially spherical/ball-shaped tartaric acid starter pellets which are suitable for preparing active substance-containing medicament formulations, as well as the pellets as such that may be obtained in this way, and their use as starting material for the preparation of active substance-containing medicament formulations. | 11-07-2013 |
| 20130302430 | MODIFIED AND IMMEDIATE RELEASE FORMULATIONS OF MEMANTINE - The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing memantine that exhibit an enhanced release profile and provide reliable absorption. The dosage forms may be used to treat mild, moderate or severe Alzheimer's disease or neuropathic pain. | 11-14-2013 |
| 20130344155 | FENOFIBRATE FORMULATION - Various fenofibrate compositions include a plurality of first granules having a high bioavailability in vivo, and a plurality of second granules having a low bioavailability in vivo. The first granules may comprise fenofibrate, from 0.3% to 10% by weight of the first granules of a first surfactant, and a first water soluble or water dispersible cellulose derivative, and the second granules may comprise fenofibrate, from 0% to 0.25% by weight of the second granules of a second surfactant, and a second water soluble or water dispersible cellulose derivative. | 12-26-2013 |
| 20140004203 | COATED DRUG SPHEROIDS AND USES THEREOF FOR ELIMINATING OR REDUCING CONDITIONS SUCH AS EMESIS AND DIARRHEA | 01-02-2014 |
| 20140030349 | GRANULES IN LIQUID DOSAGE FORM - A formulation which comprises coated granules and a water-soluble gel, wherein the coated granules comprise an oil absorbent which comprises cashew nut shell liquid, anacardic acid, cardanol, or cardol, and wherein the coated granules are suspended in the water-soluble gel. | 01-30-2014 |
| 20140065232 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR ACID-LABILE DRUGS - An enteric-coated oral dosage form comprising an acid labile active pharmaceutical ingredient where the composition is substantially free of monomeric phthalic acid esters and synthetic oils is described herein. Also provided are methods for making and using the enteric-coated oral dosage form. The disclosed pharmaceutical compositions comprise an enteric coating which includes at least one plasticizer, at least one film-forming agent and optionally at least one anti-sticking agent. | 03-06-2014 |
| 20140072644 | ANTI-MISUSE MICROPARTICULATE ORAL PHARMACEUTICAL FORM - The present invention relates to solid microparticulate oral pharmaceutical forms whose composition and structure make it possible to avoid misuse of the pharmaceutical active principle (AP) they contain. | 03-13-2014 |
| 20140079790 | MULTI-ENCAPSULATED FORMULATIONS MADE WITH OXIDIZED CELLULOSE FOR IN-SITU REACTIONS - A microsphere and methods for forming the same are disclosed. The microsphere includes modified cellulose and at least one of precursors for is-situ polymerization or endothermic/exothermic reactions. | 03-20-2014 |
| 20140093577 | COMPOSITIONS AND METHODS OF MAKING SUSTAINED RELEASE LIQUID FORMUALTIONS - The present invention includes compositions and methods for the controlled release of active agents in a shelf-stable liquid formulation by blending one or more controlled release microbeads comprising one or more active agents, preparing a dense, thixotropic solution having a density that is at, or about, the density of the one or more microbeads comprising a thixotropic agent, water and one or more preservatives under conditions that reduce bubble formation and mixing the microbeads and the thixotropic solutions in a mixer that lacks scraping paddles. | 04-03-2014 |
| 20140105994 | Microencapsulated Amino Acid Composition and the Method of Manufacturing the Microencapsulated Amino Acid Composition - The invention relates to a microencapsulated amino acid composition and methods of manufacturing this composition. Amino acids, such as branched-chain amino acids, have low water solubility, poor hydrophilicity, and poor stability. Amino acids are thus difficult to be digested and absorbed. Consequently amino acids can hardly meet human needs of consuming. This microencapsulated amino acid composition that can quickly disperse and dissolve in cold water, resulting clear solution. The method includes (1) adding coating agents, wetting agents, or other excipients to the amino acid mixture, (2) modifying the surface of microencapsulated particles to considerably accelerate the wetting speed. In this composition, the weight ratio of amino acids and excipients is from 100/0.1 to 100/10.0. | 04-17-2014 |
| 20140134259 | STABLE ORAL BENZIMIDAZOLE COMPOSITIONS AND PROCESS OF PREPARATION THEREOF - The present invention relates to stable oral compositions of one or more benzimidazole compounds and processes for their preparation. Also provided are methods for treating various gastrointestinal disorders. | 05-15-2014 |
| 20140154328 | Pharmaceutical Composition - The invention relates to an oral pharmaceutical composition comprising coated particles of a complex of at least one active agent with an ion-exchange resin, wherein said particles are coated with a bioadhesive coating layer comprising at least one bioadhesive material. The invention also relates to a process for preparing the oral pharmaceutical composition. | 06-05-2014 |
| 20140186448 | CONTROLLED RELEASE PREPARATION - A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient. | 07-03-2014 |
| 20140186449 | CONTROLLED RELEASE PREPARATION - A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient. | 07-03-2014 |
| 20140199406 | Coating Composition, Drug-Containing Particle, Solid Preparation and Method for Preparing Drug-Containing Particle - Provided are a drug-containing particle capable of suppressing dissolution of a drug in the oral cavity to suppress an unpleasant taste thereof and having excellent dissolution of the drug in the digestive tract after passing through the oral cavity; a method for preparing the drug-containing particle; a coating composition used for preparing the drug-containing particle; and a solid preparation having the drug-containing particle. More specifically, provided are a coating composition having 100 parts by weight of a cellulose-based enteric base and 50 parts by weight or less of a water-soluble cellulose ether; a drug-containing particle having a drug-containing core and a coat portion obtained by coating the core with the coating composition; a solid preparation having the drug-containing particle; and a method for preparing a drug-containing particle having a step of coating the drug-containing core with the coating composition. | 07-17-2014 |
| 20140271890 | CONTROLLED-RELEASE PHARMACEUTICAL COMPOSITION - The present invention relates to a controlled-release pharmaceutical composition which, when administered in the evening, promotes rapid sleep onset and makes it easy to wake up in the morning in a refreshing way. The composition comprises: a first portion having sleep-inducing activity, which is able to be degraded and absorbed in vivo within 5 minutes to 1 hour after administration; and a second portion having cognition-enhancing activity, which is able to be released in vivo after 4 to 8 hours from the start of absorption of the first portion. The composition, when administered in the evening, promotes rapid sleep onset and makes it easy to wake up in the morning in a refreshing way. | 09-18-2014 |
| 20140271891 | PHENYLEPHRINE RESINATE PARTICLES AND USE THEREOF IN PHARMACEUTICAL FORMULATIONS - Phenylephrine particles suitable for solid, semi solid or liquid dosage forms are disclosed. | 09-18-2014 |
| 20140271892 | PHENYLEPHRINE RESINATE PARTICLES HAVING GOOD AUC - Phenylephrine particles suitable for solid, semi solid or liquid dosage forms are disclosed. | 09-18-2014 |
| 20140314861 | SUSTAINED RELEASE BEADS AND SUSPENSIONS INCLUDING THE SAME FOR SUSTAINED DELIVERY OF ACTIVE INGREDIENTS - Sustained-released beads providing active ingredients over an extended period of time to an individual orally ingesting the sustained release beads. The sustained-release beads can be part of a suspension wherein the sustained-release beads are suspended and evenly dispersed in the suspension. Binding agents are used to form the structural framework of the sustained released beads and retain the active ingredients without chemical or electrical bonding. The components of the dispersion medium are GRAS designated, making the suspension suitable for use as a food product. | 10-23-2014 |
| 20140314862 | SUSTAINED RELEASE BEADS AND SUSPENSIONS INCLUDING THE SAME FOR SUSTAINED DELIVERY OF ACTIVE INGREDIENTS - Sustained-released beads providing active ingredients over an extended period of time to an individual orally ingesting the sustained release beads. The sustained-release beads can be part of a suspension wherein the sustained-release beads are suspended and evenly dispersed in the suspension. Binding agents are used to form the structural framework of the sustained released beads and retain the active ingredients without chemical or electrical bonding. The components of the dispersion medium are GRAS designated, making the suspension suitable for use as a food product. | 10-23-2014 |
| 20140314863 | SUSTAINED RELEASE BEADS AND SUSPENSIONS INCLUDING THE SAME FOR SUSTAINED DELIVERY OF ACTIVE INGREDIENTS - Sustained-released beads providing active ingredients over an extended period of time to an individual orally ingesting the sustained release beads. The sustained-release beads can be part of a suspension wherein the sustained-release beads are suspended and evenly dispersed in the suspension. Binding agents are used to form the structural framework of the sustained released beads and retain the active ingredients without chemical or electrical bonding. The components of the dispersion medium are GRAS designated, making the suspension suitable for use as a food product. | 10-23-2014 |
| 20140322343 | SUSTAINED-RELEASE FORMULATIONS OF TOPIRAMATE - Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided. | 10-30-2014 |
| 20140370112 | Multiparticulate L-Carnitine Compositions and Related Methods - An oral controlled-release multiparticulate dosage form comprises a plurality of individually enteric coated particulates containing an L-carnitine that independently disperse in a patient's stomach after oral ingestion and travel through the stomach and past the pyloric sphincter without substantially releasing the L-carnitine in the stomach. The individual particulates contain (a) a solid core containing the L-carnitine, (b) a subcoating containing a cellulosic water soluble polymer over the core, and (c) an enteric coating over the subcoating. The dosage form may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body. | 12-18-2014 |
| 20150037423 | ORALLY-DISINTEGRATING SOLID PREPARATION - The present invention provides an orally-disintegrating solid preparation such as a tablet produced by tabletting fine granules showing controlled release of a pharmaceutically active ingredient and an additive, and the like, and the orally-disintegrating solid preparation containing fine granules coated with a coating layer containing a polymer affording a casting film having an elongation at break of about 100-about 700%. With the preparation, breakage of fine granules during tabletting can be suppressed in the production of an orally-disintegrating solid preparation containing fine granules showing controlled release of a pharmaceutically active ingredient. | 02-05-2015 |
| 20150064262 | NITAZOXADINE COMPOSITION AND PROCESS TO PREPARE SAME - Disclosed is a pharmaceutical nitazoxanide composition comprising: (a) an immediate release fraction comprising nitazoxanide non-coated granules or non-granulated powder, and (b) a pH-dependent release fraction comprising granules of nitazoxanide coated with one or more polymers having a pH-dependent solubility. | 03-05-2015 |
| 20150118317 | FENOFIBRATE FORMULATION - Various fenofibrate dosage forms contain a plurality of beads or particles, where the beads or particles include a pharmaceutical composition comprising fenofibrate; from 0.3% to 10% by weight of the beads or particles of a surfactant; and from about 5% to about 15% by weight of the beads or particles of a water soluble or water dispersible cellulosic binder. The mass ratio of the drug to the binder in the dosage form is between about 3.5:1 and 4.5:1; and the dosage form produces a first Cmax in vivo that is between about 10% and about 50% higher than a comparative Cmax produced by a comparative dosage form. The comparative dosage form comprises the drug and the binder in a ratio of between about 5:1 and 15:1. | 04-30-2015 |
| 20150132396 | FORMULATIONS - The present invention relates to a formulation comprising a pharmaceutically active ingredient and a coating. The invention also relates to the use of the formulation in the treatment and prevention of disorders of the gastrointestinal tract. Also disclosed are methods for preparing the formulations. | 05-14-2015 |
| 20150290147 | PHENYLEPHRINE PHARMACEUTICAL FORMULATIONS AND COMPOSITIONS FOR COLONIC ABOSORPTION - The invention discloses a pharmaceutical composition comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is for oral administration wherein the composition delivers phenylephrine or a pharmaceutically acceptable salt thereof via absorption in the colon. The pharmaceutical composition comprises a core comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is in a time-dependent, pH-dependent, or colon-specific enzyme-dependent erodible layer that degrades to expose the core to release phenylephrine in the colon. In one preferred embodiment, the erodible layer encases the core. The composition optionally further comprises phenylephrine in the erodible layer or other additional layer(s). The pharmaceutical composition can further comprise one or more additional therapeutically active agents selected from one or more of the group consisting of antihistamines, analgesics, anti-pyretics, and non-steroidal anti-inflammatory agents. The invention also discloses methods of administering phenylephrine via the colon, thereby increasing the bioavailable amount of therapeutically active unconjugated phenylephrine relative to the total phenylephrine in the plasma. | 10-15-2015 |
| 20150306097 | HYDRAZALINE HYDORCHLORIDE PELLETS AND METHOD OF PREPARATION - Embodiments of a hydrazaline hydrochloride composition for treatment of hypoertension in humans each provide sustained release of hydralazine hydrochloride administered in the form of pellets, granules and tablets. Methods of preparation are disclosed. | 10-29-2015 |
| 20150342895 | HYDROXYALKYL CELLULOSE - The present invention provides a hydroxyalkyl cellulose having a viscosity of 1.10 mPa·s to 1.95 mPa·s in a 2%-concentration aqueous solution at 20° C., and a solid formulation containing the hydroxyalkyl cellulose. | 12-03-2015 |
| 20150366816 | Compositions for Treatment of Attention Deficit Hyperactivity Disorder - Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 8 hours or longer, followed by a prolonged release. | 12-24-2015 |
| 20150374831 | NOVEL ESTERIFIED CELLULOSE ETHERS OF LOW VISCOSITY - Esterified cellulose ethers which comprise (i) aliphatic monovalent acyl groups or (ii) groups of the formula —C(O)—R—COOA, wherein R is a divalent aliphatic or aromatic hydrocarbon group and A is hydrogen or a cation, or (iii) a combination of aliphatic monovalent acyl groups and groups of the formula —C(O)—R—COOA, which have a viscosity of up to 2.33 mPa·s, measured as a 2.0 wt % solution of the esterified cellulose ether in 0.43 wt % aqueous NaOH at 20° C., and which have a viscosity of up to 13 mPao·s, measured as a 10 wt % solution of the esterified cellulose ether in acetone at 20° C. are useful for preparing solid dispersions comprising drugs. | 12-31-2015 |
| 20160022596 | SUSTAINED-RELEASE FORMULATIONS OF TOPIRAMATE - Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided. | 01-28-2016 |
| 20160022649 | USE OF INHIBITORS OF MTOR TO IMPROVE VASCULAR FUNCTIONS IN APOE4 CARRIERS - Disclosed are methods and compositions for preventing cerebrovascular function dysfunction in a patient who has been identified as an ApoE4 carrier. The disclosed methods and compositions include rapamycin, a rapamycin analog, or another such inhibitor of the target of rapamycin (TOR). | 01-28-2016 |
| 20160081942 | COMPOSITION COMPRISING HYDROCORTISONE - The disclosure relates to pharmaceutical compositions useful in the treatment of adrenal insufficiency in paediatric or elderly subjects. | 03-24-2016 |
| 20160101052 | CONTROLLED RELEASE DOXYCYCLINE - The disclosure provides controlled release compositions comprising tetracyclines and in some embodiments, doxycycline. The controlled release doxycycline compositions of the invention exhibit a superior dissolution profile and provide reduce side effects such as nausea and irritation. | 04-14-2016 |
| 20160101060 | Controlled Release Doxycycline - The disclosure provides controlled release compositions comprising tetracyclines and in some embodiments, doxycycline. The controlled release doxycycline compositions of the invention exhibit a superior dissolution profile and provide reduced side effects such as nausea and irritation. | 04-14-2016 |
| 20160101119 | Controlled Release Doxycycline - The disclosure provides controlled release compositions comprising tetracyclines and in some embodiments, doxycycline. The controlled release doxycycline compositions of the invention exhibit a superior dissolution profile and provide reduce side effects such as nausea and irritation. | 04-14-2016 |
| 20160128946 | Coated Particles And Pharmaceutical Dosage Forms - The present invention relates to coated particles and pharmaceutical dosage forms comprising the active substances sensitive to environmental influences. The coating of the present invention provides stability and protection of the active substance to environmental influences and in particular from oxidation and/or environmental humidity by coating. | 05-12-2016 |
| 20160166518 | PROCESS FOR MANUFACTURING PHENYLEPHRINE RESINATE PARTICLES PHENYLEPHRINE RESINATE PARTICLES AND USE OF PHENYLEPHRINE RESINATE PARTICLES IN PHARMACEUTICAL FORMULATIONS | 06-16-2016 |
| 20160199312 | Compositions for Treatment of Attention Deficit Hyperactivity Disorder | 07-14-2016 |
